{"entity":{"id":"nct05434234","kind":"trial","name":"A Study of YL201 in Patients With Advanced Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of YL201 and Atezolizumab in advanced solid tumours, run by MediLink Therapeutics (Suzhou) Co., Ltd., now recruiting.","summary":"A Study of YL201 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05434234 by MediLink Therapeutics (Suzhou) Co., Ltd., with 312 participants planned, started 2022-05-25 and due to reach its primary completion in 2027-04-06. Interventions recorded: YL201 and YL201 and atezolizumab.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05434234","url":"https://clinicaltrials.gov/study/NCT05434234"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["yl201","atezolizumab"],"companies":["medilink"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05434234","phase":"1/2","setting":"A Phase 1A/1B, Multicenter, Nonrandomized, Open-Label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of YL201 as a Single Agent and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors","sponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","participation":[{"nct":"NCT05434234","source":"https://clinicaltrials.gov/study/NCT05434234","fetchedAt":"2026-10-07T16:53:42.604Z","studySha256":"3ac6c2a682edf1693dfb6e18503d83464b7a36fd98dc7f81e6149e9623bdee1e","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-22","leadSponsor":"MediLink Therapeutics (Suzhou) Co., Ltd.","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":312,"enrolmentType":"ESTIMATED","siteCount":45,"recruitingSiteCount":38,"countries":["Canada","China","France","Poland","Spain","United States"]}],"started":"2022-05-25","startedType":"actual","enrolled":312,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05434234/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"yl201","kind":"drug","name":"YL201","route":"/drugs/yl201/"}],"company":[{"id":"medilink","kind":"company","name":"MediLink Therapeutics","route":"/companies/medilink/"}]}}